Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Clinical and genetic analysis of melanomas arising in acral sites.

Zaremba A, Murali R, Jansen P, Möller I, Sucker A, Paschen A, Zimmer L, Livingstone E, Brinker TJ, Hadaschik E, Franklin C, Roesch A, Ugurel S, Schadendorf D, Griewank KG, Cosgarea I.

Eur J Cancer. 2019 Aug 13;119:66-76. doi: 10.1016/j.ejca.2019.07.008. [Epub ahead of print]

PMID:
31419753
2.

Assessment of Nonradioactive Multispectral Optoacoustic Tomographic Imaging With Conventional Lymphoscintigraphic Imaging for Sentinel Lymph Node Biopsy in Melanoma.

Stoffels I, Jansen P, Petri M, Goerdt L, Brinker TJ, Griewank KG, Poeppel TD, Schadendorf D, Klode J.

JAMA Netw Open. 2019 Aug 2;2(8):e199020. doi: 10.1001/jamanetworkopen.2019.9020.

PMID:
31411710
3.

The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma.

Phung B, Cieśla M, Sanna A, Guzzi N, Beneventi G, Cao Thi Ngoc P, Lauss M, Cabrita R, Cordero E, Bosch A, Rosengren F, Häkkinen J, Griewank K, Paschen A, Harbst K, Olsson H, Ingvar C, Carneiro A, Tsao H, Schadendorf D, Pietras K, Bellodi C, Jönsson G.

Cell Rep. 2019 Jun 18;27(12):3573-3586.e7. doi: 10.1016/j.celrep.2019.05.069.

4.

An Animal Model of Cutaneous Cyst Development Enables the Identification of Three Quantitative Trait Loci, Including the Homologue of a Human Locus (TRICY1).

Cosgarea I, Koelsch B, Fischer C, Griewank KG, van den Berg L, Kutritz A, Schadendorf D, Kindler-Röhrborn A.

J Invest Dermatol. 2019 Apr 27. pii: S0022-202X(19)31495-2. doi: 10.1016/j.jid.2019.03.1154. [Epub ahead of print] No abstract available.

PMID:
31039361
5.

Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi.

Jansen P, Cosgarea I, Murali R, Möller I, Sucker A, Franklin C, Paschen A, Zaremba A, Brinker TJ, Stoffels I, Schadendorf D, Klode J, Hadaschik E, Griewank KG.

Cancers (Basel). 2019 Apr 16;11(4). pii: E546. doi: 10.3390/cancers11040546.

6.

Proton radiotherapy in advanced malignant melanoma of the conjunctiva.

Scholz SL, Hérault J, Stang A, Griewank KG, Meller D, Thariat J, Steuhl KP, Westekemper H, Sauerwein W.

Graefes Arch Clin Exp Ophthalmol. 2019 Jun;257(6):1309-1318. doi: 10.1007/s00417-019-04286-2. Epub 2019 Mar 27.

PMID:
30919076
7.

Genome-wide methylation profiling and copy number analysis in atypical fibroxanthomas and pleomorphic dermal sarcomas indicate a similar molecular phenotype.

Koelsche C, Stichel D, Griewank KG, Schrimpf D, Reuss DE, Bewerunge-Hudler M, Vokuhl C, Dinjens WNM, Petersen I, Mittelbronn M, Cuevas-Bourdier A, Buslei R, Pfister SM, Flucke U, Mechtersheimer G, Mentzel T, von Deimling A.

Clin Sarcoma Res. 2019 Feb 14;9:2. doi: 10.1186/s13569-019-0113-6. eCollection 2019.

8.

Prognostic significance of NAB2-STAT6 fusion variants and TERT promotor mutations in solitary fibrous tumors/hemangiopericytomas of the CNS: not (yet) clear.

Vogels R, Macagno N, Griewank K, Groenen P, Verdijk M, Fonville J, Kusters B; French CNS SFT/HPC Consortium; Dutch CNS SFT/HPC Consortium, Figarella-Branger D, Wesseling P, Bouvier C, Flucke U.

Acta Neuropathol. 2019 Apr;137(4):679-682. doi: 10.1007/s00401-019-01968-3. Epub 2019 Feb 2. No abstract available.

PMID:
30761420
9.

[Digital papillary adenocarcinoma : Four case reports with brief literature review].

Held L, Mentzel T, Paredes BE, Griewank KG, Itzlinger-Monshi B, Rütten A.

Hautarzt. 2019 Mar;70(3):204-209. doi: 10.1007/s00105-018-4313-4. German.

PMID:
30478600
10.

Re: van Poppelen et al.: Genetic background of iris melanomas and iris melanocytic tumors of uncertain malignant potential (Ophthalmology. 2018;125:904-912).

Scholz SL, Murali R, Westekemper H, Schadendorf D, Griewank KG.

Ophthalmology. 2018 Nov;125(11):e78-e79. doi: 10.1016/j.ophtha.2018.05.021. No abstract available.

PMID:
30318043
11.

Melanoma.

Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S.

Lancet. 2018 Sep 15;392(10151):971-984. doi: 10.1016/S0140-6736(18)31559-9. Review. Erratum in: Lancet. 2019 Feb 23;393(10173):746.

PMID:
30238891
12.

Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance.

Horn S, Leonardelli S, Sucker A, Schadendorf D, Griewank KG, Paschen A.

J Natl Cancer Inst. 2018 Jun 1;110(6):677-681. doi: 10.1093/jnci/djx271.

PMID:
29917141
13.

Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling.

Griewank KG, Koelsche C, van de Nes JAP, Schrimpf D, Gessi M, Möller I, Sucker A, Scolyer RA, Buckland ME, Murali R, Pietsch T, von Deimling A, Schadendorf D.

Clin Cancer Res. 2018 Sep 15;24(18):4494-4504. doi: 10.1158/1078-0432.CCR-18-0763. Epub 2018 Jun 11.

PMID:
29891723
14.

NF1 mutations in conjunctival melanoma.

Scholz SL, Cosgarea I, Süßkind D, Murali R, Möller I, Reis H, Leonardelli S, Schilling B, Schimming T, Hadaschik E, Franklin C, Paschen A, Sucker A, Steuhl KP, Schadendorf D, Westekemper H, Griewank KG.

Br J Cancer. 2018 May;118(9):1243-1247. doi: 10.1038/s41416-018-0046-5. Epub 2018 Mar 21.

15.

GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma.

Moore AR, Ran L, Guan Y, Sher JJ, Hitchman TD, Zhang JQ, Hwang C, Walzak EG, Shoushtari AN, Monette S, Murali R, Wiesner T, Griewank KG, Chi P, Chen Y.

Cell Rep. 2018 Feb 27;22(9):2455-2468. doi: 10.1016/j.celrep.2018.01.081.

16.

Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.

Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT; TCGA Research Network, Cherniack AD, Benz C, Mills GB, Verhaak RGW, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfield L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SE.

Cancer Cell. 2018 Jan 8;33(1):151. doi: 10.1016/j.ccell.2017.12.013. No abstract available.

17.

Intraventricular melanocytoma diagnosis confirmed by gene mutation profile.

Knappe UJ, Tischoff I, Tannapfel A, Reinbold WD, Möller I, Sucker A, Schadendorf D, Griewank KG, van de Nes JAP.

Neuropathology. 2018 Jun;38(3):288-292. doi: 10.1111/neup.12443. Epub 2017 Dec 11.

PMID:
29226425
18.

Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles.

Griewank KG, Wiesner T, Murali R, Pischler C, Müller H, Koelsche C, Möller I, Franklin C, Cosgarea I, Sucker A, Schadendorf D, Schaller J, Horn S, Brenn T, Mentzel T.

Mod Pathol. 2018 Mar;31(3):418-428. doi: 10.1038/modpathol.2017.146. Epub 2017 Nov 3.

19.

The genetic basis for most patients with pustular skin disease remains elusive.

Mössner R, Wilsmann-Theis D, Oji V, Gkogkolou P, Löhr S, Schulz P, Körber A, Prinz JC, Renner R, Schäkel K, Vogelsang L, Peters KP, Philipp S, Reich K, Ständer H, Jacobi A, Weyergraf A, Kingo K, Kõks S, Gerdes S, Steinz K, Schill T, Griewank KG, Müller M, Frey S, Ebertsch L, Uebe S, Sticherling M, Sticht H, Hüffmeier U.

Br J Dermatol. 2018 Mar;178(3):740-748. doi: 10.1111/bjd.15867. Epub 2018 Jan 22.

PMID:
28887889
20.

Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.

Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT; TCGA Research Network, Cherniack AD, Benz C, Mills GB, Verhaak RGW, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfield L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SE.

Cancer Cell. 2017 Aug 14;32(2):204-220.e15. doi: 10.1016/j.ccell.2017.07.003. Erratum in: Cancer Cell. 2018 Jan 8;33(1):151.

21.

Oxygenation Status in Chronic Leg Ulcer After Topical Hemoglobin Application May Act as a Surrogate Marker to Find the Best Treatment Strategy and to Avoid Ineffective Conservative Long-term Therapy.

Petri M, Stoffels I, Griewank K, Jose J, Engels P, Schulz A, Pötzschke H, Jansen P, Schadendorf D, Dissemond J, Klode J.

Mol Imaging Biol. 2018 Feb;20(1):124-130. doi: 10.1007/s11307-017-1103-9.

PMID:
28702902
22.

Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma.

Scholz SL, Möller I, Reis H, Süßkind D, van de Nes JAP, Leonardelli S, Schilling B, Livingstone E, Schimming T, Paschen A, Sucker A, Murali R, Steuhl KP, Schadendorf D, Westekemper H, Griewank KG.

Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3464-3470. doi: 10.1167/iovs.17-21838.

PMID:
28700778
23.

Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.

Sucker A, Zhao F, Pieper N, Heeke C, Maltaner R, Stadtler N, Real B, Bielefeld N, Howe S, Weide B, Gutzmer R, Utikal J, Loquai C, Gogas H, Klein-Hitpass L, Zeschnigk M, Westendorf AM, Trilling M, Horn S, Schilling B, Schadendorf D, Griewank KG, Paschen A.

Nat Commun. 2017 May 31;8:15440. doi: 10.1038/ncomms15440.

24.

Epidermal growth factor receptor gaining impact in cutaneous squamous cell carcinoma.

Griewank KG.

Br J Dermatol. 2017 May;176(5):1126-1127. doi: 10.1111/bjd.15210. No abstract available.

PMID:
28504402
25.

Activating CYSLTR2 and PLCB4 Mutations in Primary Leptomeningeal Melanocytic Tumors.

van de Nes JAP, Koelsche C, Gessi M, Möller I, Sucker A, Scolyer RA, Buckland ME, Pietsch T, Murali R, Schadendorf D, Griewank KG.

J Invest Dermatol. 2017 Sep;137(9):2033-2035. doi: 10.1016/j.jid.2017.04.022. Epub 2017 May 10. No abstract available.

26.

SF3B1 and BAP1 mutations in blue nevus-like melanoma.

Griewank KG, Müller H, Jackett LA, Emberger M, Möller I, van de Nes JA, Zimmer L, Livingstone E, Wiesner T, Scholz SL, Cosgarea I, Sucker A, Schimming T, Hillen U, Schilling B, Paschen A, Reis H, Mentzel T, Kutzner H, Rütten A, Murali R, Scolyer RA, Schadendorf D.

Mod Pathol. 2017 Jul;30(7):928-939. doi: 10.1038/modpathol.2017.23. Epub 2017 Apr 14.

27.

Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.

Cosgarea I, Ugurel S, Sucker A, Livingstone E, Zimmer L, Ziemer M, Utikal J, Mohr P, Pfeiffer C, Pföhler C, Hillen U, Horn S, Schadendorf D, Griewank KG, Roesch A.

Oncotarget. 2017 Jun 20;8(25):40683-40692. doi: 10.18632/oncotarget.16542.

28.

Next-Generation Sequencing to Guide Treatment of Advanced Melanoma.

Griewank KG, Schilling B.

Am J Clin Dermatol. 2017 Jun;18(3):303-310. doi: 10.1007/s40257-017-0260-6. Review.

PMID:
28229402
29.

Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi.

Möller I, Murali R, Müller H, Wiesner T, Jackett LA, Scholz SL, Cosgarea I, van de Nes JA, Sucker A, Hillen U, Schilling B, Paschen A, Kutzner H, Rütten A, Böckers M, Scolyer RA, Schadendorf D, Griewank KG.

Mod Pathol. 2017 Mar;30(3):350-356. doi: 10.1038/modpathol.2016.201. Epub 2016 Dec 9.

30.

Biomarkers in melanoma.

Griewank KG.

Scand J Clin Lab Invest Suppl. 2016;245:S104-12. doi: 10.1080/00365513.2016.1210336. Epub 2016 Jul 28. Review.

PMID:
27467728
31.

Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNA.

Stiller M, Sucker A, Griewank K, Aust D, Baretton GB, Schadendorf D, Horn S.

Oncotarget. 2016 Sep 13;7(37):59115-59128. doi: 10.18632/oncotarget.10827.

32.

Melanoma diagnosed in lesions previously treated by laser therapy.

Delker S, Livingstone E, Schimming T, Schadendorf D, Griewank KG.

J Dermatol. 2017 Jan;44(1):23-28. doi: 10.1111/1346-8138.13484. Epub 2016 Jun 27.

PMID:
27345456
33.

High TERT promoter mutation frequency in non-acral cutaneous metastatic melanoma.

Ekedahl H, Lauss M, Olsson H, Griewank KG, Schadendorf D, Ingvar C, Jönsson G.

Pigment Cell Melanoma Res. 2016 Sep;29(5):598-600. doi: 10.1111/pcmr.12500. Epub 2016 Aug 1. No abstract available.

PMID:
27301352
34.

[Molecular and immunohistochemical diagnostics in melanoma].

Schilling B, Griewank KG.

Hautarzt. 2016 Jul;67(7):511-8. doi: 10.1007/s00105-016-3807-1. Review. German.

PMID:
27270408
35.

Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency.

Zhao F, Sucker A, Horn S, Heeke C, Bielefeld N, Schrörs B, Bicker A, Lindemann M, Roesch A, Gaudernack G, Stiller M, Becker JC, Lennerz V, Wölfel T, Schadendorf D, Griewank K, Paschen A.

Cancer Res. 2016 Aug 1;76(15):4347-58. doi: 10.1158/0008-5472.CAN-16-0008. Epub 2016 Jun 3.

36.

Diagnosing a Primary Leptomeningeal Melanoma by Gene Mutation Signature.

van de Nes J, Wrede K, Ringelstein A, Stiller M, Horn S, Sucker A, Möller I, Scholz SL, Murali R, Gessi M, Schadendorf D, Griewank KG.

J Invest Dermatol. 2016 Jul;136(7):1526-1528. doi: 10.1016/j.jid.2016.03.031. Epub 2016 Apr 7. No abstract available.

37.

Oncogene status as a diagnostic tool in ocular and cutaneous melanoma.

Griewank KG, Schilling B, Scholz SL, Metz CH, Livingstone E, Sucker A, Möller I, Reis H, Franklin C, Cosgarea I, Hillen U, Steuhl KP, Schadendorf D, Westekemper H, Zimmer L.

Eur J Cancer. 2016 Apr;57:112-7. doi: 10.1016/j.ejca.2016.01.010. Epub 2016 Feb 23.

PMID:
26918736
38.

Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system.

van de Nes J, Gessi M, Sucker A, Möller I, Stiller M, Horn S, Scholz SL, Pischler C, Stadtler N, Schilling B, Zimmer L, Hillen U, Scolyer RA, Buckland ME, Lauriola L, Pietsch T, Waha A, Schadendorf D, Murali R, Griewank KG.

J Neurooncol. 2016 May;127(3):435-44. doi: 10.1007/s11060-015-2052-2. Epub 2016 Jan 7.

39.

Metastatic status of sentinel lymph nodes in melanoma determined noninvasively with multispectral optoacoustic imaging.

Stoffels I, Morscher S, Helfrich I, Hillen U, Leyh J, Burton NC, Sardella TC, Claussen J, Poeppel TD, Bachmann HS, Roesch A, Griewank K, Schadendorf D, Gunzer M, Klode J.

Sci Transl Med. 2015 Dec 9;7(317):317ra199. doi: 10.1126/scitranslmed.aad1278. Erratum in: Sci Transl Med. 2015 Dec 23;7(319):319er8. Lehy, Julia [corrected to Leyh, Julia].

PMID:
26659573
40.

Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway.

Murali R, Chandramohan R, Möller I, Scholz SL, Berger M, Huberman K, Viale A, Pirun M, Socci ND, Bouvier N, Bauer S, Artl M, Schilling B, Schimming T, Sucker A, Schwindenhammer B, Grabellus F, Speicher MR, Schaller J, Hillen U, Schadendorf D, Mentzel T, Cheng DT, Wiesner T, Griewank KG.

Oncotarget. 2015 Nov 3;6(34):36041-52. doi: 10.18632/oncotarget.5936.

41.

Frequent TERT Promoter Mutations in Ocular Surface Squamous Neoplasia.

Scholz SL, Thomasen H, Reis H, Möller I, Darawsha R, Müller B, Dekowski D, Sucker A, Schilling B, Schadendorf D, Steuhl KP, Paschen A, Westekemper H, Meller D, Griewank KG.

Invest Ophthalmol Vis Sci. 2015 Sep;56(10):5854-61. doi: 10.1167/iovs.15-17469.

PMID:
26348634
42.

Analysis of SDHD promoter mutations in various types of melanoma.

Scholz SL, Horn S, Murali R, Möller I, Sucker A, Sondermann W, Stiller M, Schilling B, Livingstone E, Zimmer L, Reis H, Metz CH, Zeschnigk M, Paschen A, Steuhl KP, Schadendorf D, Westekemper H, Griewank KG.

Oncotarget. 2015 Sep 22;6(28):25868-82. doi: 10.18632/oncotarget.4665.

43.

Corticosteroids augment BRAF inhibitor vemurafenib induced lymphopenia and risk of infection.

Sondermann W, Griewank KG, Schilling B, Livingstone E, Leyh JC, Rompoti N, Cosgarea I, Schimming T, Schadendorf D, Zimmer L, Hillen U.

PLoS One. 2015 Apr 21;10(4):e0124590. doi: 10.1371/journal.pone.0124590. eCollection 2015.

44.

Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.

Zimmer L, Vaubel J, Mohr P, Hauschild A, Utikal J, Simon J, Garbe C, Herbst R, Enk A, Kämpgen E, Livingstone E, Bluhm L, Rompel R, Griewank KG, Fluck M, Schilling B, Schadendorf D.

PLoS One. 2015 Mar 11;10(3):e0118564. doi: 10.1371/journal.pone.0118564. eCollection 2015.

45.

Response.

Griewank KG, Murali R, Scherag A, Schadendorf D.

J Natl Cancer Inst. 2015 Mar 9;107(4). pii: djv051. doi: 10.1093/jnci/djv051. Print 2015 Apr. No abstract available.

PMID:
25755156
46.

Panel sequencing melanomas.

Griewank KG, Schadendorf D.

J Invest Dermatol. 2015 Feb;135(2):335-336. doi: 10.1038/jid.2014.420.

47.

[Molecular diagnostics of melanomas].

Griewank KG.

Pathologe. 2015 Feb;36(1):30-6. doi: 10.1007/s00292-014-2054-4. Review. German.

PMID:
25491471
48.

Reply to the letters to the editor 'Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma' by Diwakar et al.

Schilling B, Sondermann W, Griewank KG, Livingstone E, Zimmer L, Hillen U, Schadendorf D.

Ann Oncol. 2015 Jan;26(1):250-1; discussion 251-2. doi: 10.1093/annonc/mdu502. Epub 2014 Oct 29. No abstract available.

PMID:
25355721
49.

Genetic evolution of T-cell resistance in the course of melanoma progression.

Sucker A, Zhao F, Real B, Heeke C, Bielefeld N, Maβen S, Horn S, Moll I, Maltaner R, Horn PA, Schilling B, Sabbatino F, Lennerz V, Kloor M, Ferrone S, Schadendorf D, Falk CS, Griewank K, Paschen A.

Clin Cancer Res. 2014 Dec 15;20(24):6593-604. doi: 10.1158/1078-0432.CCR-14-0567. Epub 2014 Oct 7.

50.

Angioplasmacellular hyperplasia - a new histopathologic clue for anogenital herpes simplex recidivans in immunocompromised patients?

Schimming TT, Griewank KG, Esser S, Schadendorf D, Hillen U.

Am J Dermatopathol. 2014 Oct;36(10):822-6. doi: 10.1097/DAD.0000000000000070.

PMID:
25243397

Supplemental Content

Loading ...
Support Center